Hetero Ring Is Six-membered Having Two Or More Ring Hetero Atoms Of Which At Least One Is Nitrogen (e.g., Selenazines, Etc.) Patents (Class 544/1)
  • Patent number: 11512262
    Abstract: The present disclosure relates generally to antioxidants. More particularly, the present disclosure relates to lubricating compositions comprising an antioxidant.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: November 29, 2022
    Assignee: University of Ottawa
    Inventors: Derek Andrew Pratt, Evan Haidasz
  • Patent number: 9951271
    Abstract: The present invention relates to a process for making an asymmetric fluorophore. The asymmetric fluorophore is useful as a stain for staining live cells or fixed cell and provides whole-cell staining of such cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 24, 2018
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE
    Inventors: Christopher Arnatt, John Elliott
  • Patent number: 9771383
    Abstract: A modified opioid is provided comprising modified morphine molecules, wherein for each morphine molecule, one or more carbon atoms are replaced with silicon atoms. A method is further provided for modifying an opioid comprising morphine molecules, said method comprising the step of replacing one or more carbon atoms with silicon atoms.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: September 26, 2017
    Inventor: James Andrew Leskosek
  • Patent number: 9513294
    Abstract: A library of novel amino-triazolyl-BODIPY compounds is described. Particular compounds of the library serve as selective fluorescent probes for human serum albumin (HSA) and for live primary neurons. The fluorescent probe for HSA binds uniquely and specifically to the fatty acid site 1 of HSA, and thus proves a valuable and unique probe for drugs that bind to such a site on HSA. Methods of synthesis for the library compounds are also described.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: December 6, 2016
    Assignees: National University of Singapore, Agency for Science, Technology and Research
    Inventors: Young-Tae Chang, Jun Cheng Er, Cheryl Kit Mun Leong, Seong Wook Yun, Marc Vendrell Escobar, Mui Kee Tang
  • Patent number: 8883800
    Abstract: The present invention relates to substituted quinazolines of formula (I): wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • Patent number: 8871520
    Abstract: The invention provides a method of detecting uracil. The method comprises reacting uracil with a compound represented by the formula (I) in the presence of an oxidant and a base to produce a fluorescent compound represented by the formula (II).
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: October 28, 2014
    Assignee: Nagasaki University
    Inventors: Masaaki Kai, Takayuki Shibata
  • Patent number: 8703437
    Abstract: The present invention provides fluorogenic substrates and methods of use in detecting and analyzing phospholipase C isozyme (PLC) activity.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: April 22, 2014
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Qisheng Zhang, Wei Gang Huang, John Sondek, Stephanie Hicks
  • Patent number: 8663804
    Abstract: The present invention deals with a flexible printed wiring board in the form of a printed wiring board wherein the conductive elements are fully encapsulated by an epoxy adhesive comprising a novel aromatic di-isoimide chemical compound. The conductive elements are thereby protected. The flexible printed wiring board is readily cured at a temperature in the range of 100 to 250° C. However, before curing, by virtue of the latent cure feature of the epoxy adhesive, the adhesive component of the printed wiring board has an extended shelf life, and avoids premature curing during processing.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 4, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventor: George Elias Zahr
  • Patent number: 8580386
    Abstract: The present invention deals with a laminate useful for forming fully encapsulated flexible printed wiring boards. The laminate comprises a dielectric substrate coated with a curable composition comprising an epoxy and a novel aromatic di-isoimide chemical compound. The curable composition provides the benefit of thermal latency, improving shelf-life, and reducing premature curing during processing. Fully encapsulated printed wiring boards are also disclosed.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: November 12, 2013
    Assignee: E I du Pont de Nemours and Company
    Inventor: George Elias Zahr
  • Patent number: 8557847
    Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: October 15, 2013
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Christian Andrew Baumann, Michael David Gaul, Dana L. Johnson, Robert W. Tuman
  • Patent number: 8541423
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: September 24, 2013
    Assignee: Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Patent number: 8524936
    Abstract: The present invention relates to a novel manufacturing process of pharmaceutically active compound of formula I used as oral anti-diabetic drug. Starting from L-aspartic acid derivate of formula IV the invention describes preparation of the chiral (R)-?-amino acid of formula II known as a precursor in the synthesis of Sitagliptin (formula I).
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: September 3, 2013
    Inventor: Milan Soukup
  • Patent number: 8524896
    Abstract: A compound of the formula (I) where, for example, W, X and Y are each CH; R1 and R6 together with the adjacent nitrogen forms a 3 to 10-membered saturated ring, wherein the ring may contain, in addition to the nitrogen and carbon ring members, 1, 2 or 3 heteroatoms and/or heteroatom groups as ring members, independently of one another, selected from the group consisting of sulfur, CO, SO, SO2 and N—R7 and/or the ring may carry 1, 2 or 3 radicals, independently of one another, each selected, for example, from the group consisting of halogen, cyano, nitro, amino, and C1-C6-alkyl. R2 is, for example, halogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy or C1-C6-alkoxy-C1-C6-alkoxy, and R7 is for example, R10C(?O), C1-C6 alkyl or C1-C6-haloalkyl; and/or salts thereof; and their use as pesticidal agents.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: September 3, 2013
    Assignee: Syngenta Crop Protection LLC
    Inventors: Peter Maienfisch, Ottmar Hueter, Peter Renold, Werner Zambach, Thomas Pitterna
  • Patent number: 8519125
    Abstract: Compositions and methods are disclosed for substantially dry storage at ambient or elevated temperatures of biological samples such as nucleic acids, proteins and cells in a form from which the samples can be substantially recovered, using a dissolvable or dissociable dry storage matrix comprising a borate composition and a stabilizer as disclosed, such as any of a number of zwitterionic stabilizers.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: August 27, 2013
    Assignee: Biomatrica, Inc.
    Inventors: Scott E. Whitney, Sohela De Rozieres, Rolf Muller
  • Patent number: 8512755
    Abstract: A ligand design allows compact nanoparticle materials, such as quantum dots (QDs), with excellent colloidal stability over a wide range of pH and under high salt concentrations. Self-assembled biomolecular conjugates with QDs can be obtained which are stable in biological environments. Energy transfer with these ligands is maximized by minimizing distances between QDs/nanoparticles and donors/acceptors directly attached to the ligands or assembled on their surfaces.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: August 20, 2013
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Igor L. Medintz, Kimihiro Susumu, Michael H. Stewart
  • Patent number: 8450398
    Abstract: The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: May 28, 2013
    Assignee: Constar International, Inc.
    Inventor: Girish N. Deshpande
  • Patent number: 8362239
    Abstract: Disclosed are an oligomer and a phthalonitrile monomer having the formulas: M is a metal or H. The value n is an integer greater than or equal to 1 for the oligomer and greater than or equal to 0 for the phthalonitrile monomer. Ar1 and Ar2 are independently selected aromatic- or heterocyclic-containing groups. Ar1, Ar2, or both are heteroaromatic or heterocyclic groups containing a nitrogen, sulfur, or oxygen heteroatom. Also disclosed are thermosets and pyrolyzed materials made from the phthalonitrile monomer.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: January 29, 2013
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Matthew Laskoski, Teddy M Keller
  • Publication number: 20120328530
    Abstract: A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.
    Type: Application
    Filed: March 11, 2011
    Publication date: December 27, 2012
    Applicant: PHARMALUCIA LIMITED
    Inventor: Mark Wainwright
  • Patent number: 8222403
    Abstract: Disclosed are an oligomer and a phthalonitrile monomer having the formulas: M is a metal or H. The value n is an integer greater than or equal to 1 for the oligomer and greater than or equal to 0 for the phthalonitrile monomer. Ar1 and Ar2 are independently selected aromatic- or heterocyclic-containing groups. Ar1, Ar2, or both are heteroaromatic or heterocyclic groups containing a nitrogen, sulfur, or oxygen heteroatom. Also disclosed are thermosets and pyrolyzed materials made from the phthalonitrile monomer.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: July 17, 2012
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Matthew Laskoski, Teddy M Keller
  • Patent number: 8207332
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: June 26, 2012
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Patent number: 8193388
    Abstract: Disclosed herein are tellurium metal-organic precursors and methods for depositing tellurium-containing films on a substrate.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: June 5, 2012
    Assignee: American Air Liquide, Inc.
    Inventors: Benjamin J. Feist, Christian Dussarrat
  • Patent number: 8188269
    Abstract: The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2-1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 29, 2012
    Assignee: Luminex Corporation
    Inventors: Ananda G. Lugade, Kurt D. Hoffacker, Adam J. Jenkins, Karri L. Michael-Ballard, Leonid Patsenker, Ewald Terpetschnig, Veronica D. Thomason, Ralph McDade
  • Patent number: 8133847
    Abstract: The present invention relates to a method of controlling plants or inhibiting plant growth which comprises applying to the plants or to the locus thereof a herbicidally effective amount of a compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to herbicidal compositions comprising compounds of formula (I) and to certain novel pyrido[2,3-b]pyrazines.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: March 13, 2012
    Assignee: Syngenta Limited
    Inventors: Neil Brian Carter, Matthew Robert Cordingley, Patrick Jelf Crowley, Michael Drysdale Turnbull
  • Patent number: 8134146
    Abstract: The present invention relates to heterocyclic radicals or diradicals, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, to the use thereof to organic semiconductive materials and to electronic and optoelectronic components.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: March 13, 2012
    Assignee: Novaled AG
    Inventors: Michael Limmert, Olaf Zeika, Martin Ammann, Horst Hartmann, Ansgar Werner
  • Patent number: 8105504
    Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula (I) wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 31, 2012
    Assignee: BASF SE
    Inventors: Michèle Gerster, Peter Nesvadba
  • Publication number: 20110279019
    Abstract: Novel organic compounds comprising azaborine are provided. In particular, the compounds comprise a dibenzo-1,4,-azaborine core having a phenyl substituent on the boron atom, and aryl or heteroaryl substituents at positions 2 and 6 of the phenyl substituent. These compounds may be advantageously used in organic light-emitting devices to provide improved efficiency and lifetime.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 17, 2011
    Applicant: UNIVERSAL DISPLAY CORPORATION
    Inventors: Gregg Kottas, Raymond C. Kwong
  • Patent number: 8008315
    Abstract: The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: August 30, 2011
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Philippe G. Nantermet, Hemaka Anthony Rajapakse, Harold G. Selnick
  • Patent number: 7981874
    Abstract: The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 19, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joshua Close, Jonathan Grimm, Richard W. Heidebrecht, Jr., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Scott Peterson, Phieng Siliphaivanh, Paul J. Tempest, Kevin J. Wilson, David J. Witter
  • Patent number: 7977476
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: July 12, 2011
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Patent number: 7901667
    Abstract: The present invention relates to compounds having the general formula: Y-L-BFR-X wherein BFR is a bridged fused ring system; Y is a targeting group; L is optionally present and is a linker for coupling Y to BFR; and X is halogen (e.g., radiohalogen) or a functional group for labelling.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: March 8, 2011
    Assignee: Mallinckrodt Inc.
    Inventors: Jacobus Donatus M. Herscheid, Joost Verbeek
  • Patent number: 7863058
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: January 4, 2011
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Publication number: 20100233279
    Abstract: Disclosed are novel analogues of the natural product radicicol A of formulae I, .Ia, pi, Ha, lib and HI, pharmaceutical compositions comprising the compounds. The compounds of the invention are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase-mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase-mediated disorders and synthetic processes for the preparation of the compounds.
    Type: Application
    Filed: June 5, 2008
    Publication date: September 16, 2010
    Inventors: Nicolas Winssinger, Sofia Barluenga
  • Patent number: 7795279
    Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: September 14, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Shelley K. Ballentine, Christian Andrew Baumann, Jinsheng Chen, Carl R. Illig, Sanath K. Meegalla, M. Jonathan Rudolph, Robert W. Tuman, Mark J. Wall, Kenneth Wilson, Dana L. Johnson
  • Patent number: 7728128
    Abstract: The present invention concerns novel dibenzo[c,h][1,5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 1, 2010
    Assignees: Institut National de la Sante et de la Recherche Medicate (INSERM), Institut Curie, Centre National de la Recherche Scientifique (C.N.R.S.), Commissariat a l'Energie Atomique
    Inventors: Andreï Popov, David Grierson, Jean-Claude Florent
  • Publication number: 20100016583
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods that can be used to treat pathologies that are due to copper overload or to the presence of reactive oxygen species.
    Type: Application
    Filed: October 6, 2009
    Publication date: January 21, 2010
    Applicant: The Curators of the University of Missouri
    Inventors: Kavita K. Katti, Kannan Raghuraman, Stan W. Casteel, Kattesh V. Katti
  • Publication number: 20100009935
    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
    Type: Application
    Filed: July 16, 2009
    Publication date: January 14, 2010
    Applicant: SEQUOIA PHARMACEUTICALS
    Inventors: John W. Erickson, Michael Eissenstat, Abelardo Silva, Sergei Gulnik
  • Patent number: 7629108
    Abstract: A resist composition comprising as a quencher a nitrogen-containing organic compound bearing a nitrogen-containing heterocycle and having a molecular weight of at least 380 exhibits a high resolution and satisfactory mask coverage dependence and is useful in microfabrication using electron beam or deep-UV.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: December 8, 2009
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Takeru Watanabe, Youichi Ohsawa, Masaki Ohashi, Wataru Kusaki, Tomohiro Kobayashi
  • Publication number: 20090256127
    Abstract: Disclosed herein are tellurium metal-organic precursors and methods for depositing tellurium-containing films on a substrate.
    Type: Application
    Filed: April 14, 2009
    Publication date: October 15, 2009
    Applicant: American Air Liquide, Inc.
    Inventors: Benjamin J. FEIST, Christian DUSSARRAT
  • Publication number: 20090215225
    Abstract: Precursors for use in depositing tellurium-containing films on substrates such as wafers or other microelectronic device substrates, as well as associated processes of making and using such precursors, and source packages of such precursors. The precursors are useful for deposition of chalcogenide thin films in the manufacture of nonvolatile Phase Change Memory (PCM), by deposition techniques such as chemical vapor deposition (CVD) and atomic layer deposition (ALD).
    Type: Application
    Filed: February 24, 2009
    Publication date: August 27, 2009
    Applicant: ADVANCED TECHNOLOGY MATERIALS, INC.
    Inventors: Matthias Stender, Chongying Xu, Tianniu Chen, William Hunks, Philip S.H. Chen, Jeffrey F. Roeder, Thomas H. Baum
  • Patent number: 7528137
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: May 5, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Bainian Feng, Gustave Bergnes, David J. Morgans, Jr., Dashyant Dhanak, Steven David Knight, Michael Gerard Darcy
  • Patent number: 7504499
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: March 17, 2009
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Patent number: 7498436
    Abstract: This present invention relates to prodrug compounds of the formula (Y) and pharmaceutical salts thereof: where RN, R1, R2, R3R4 and RC are defined herein, which are useful in treating Alzheimer's disease and other similar diseases.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: March 3, 2009
    Assignees: Pharmacia & Upjohn Company LLC, Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Barbara Jagodzinska, Michel Maillard, James P. Beck, Ruth E. TenBrink, Daniel Getman
  • Patent number: 7407948
    Abstract: Phonoselenazinium compounds of Formula (1): and their use in photodynamic therapy (PDT), particularly as anti-infectives, as anti-cancer agents, and as sterilising agents both for direct use and in combination with a polymer, wherein: A and B are each independently selected from:
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: August 5, 2008
    Assignee: Photopharmica Limited
    Inventors: John Griffiths, Stephen Anthony Gorman, Andrea Bell
  • Patent number: 7361755
    Abstract: This invention pertains to a novel process for preparing sterically hindered N-substituted alkyloxyamines from alkenes by the transition-metal-catalyzed reaction of a intermediate alkylborane with a sterically hindered nitroxyl radical.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: April 22, 2008
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Stephen Daniel Pastor, Sai Ping Shum
  • Patent number: 7345301
    Abstract: The present invention describes new types of material mixtures composed of at least two substances, one serving as a matrix material and the other being an emission material capable of emission, the latter comprising at least one element of atomic number greater than 20, and the use thereof in organic electronic components such as electroluminescent elements and displays.
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: March 18, 2008
    Assignee: Merck Patent GmbH
    Inventors: Anja Gerhard, Horst Vestweber, Philipp Stössel, Susanne Heun, Hubert Spreitzer
  • Patent number: 7294738
    Abstract: The present invention discloses novel steroid mimics wherein a tri- or tetravalent phosphorous atom is isosterically substituted at any one of the seventeen positions occupied by the carbon atom in the steroidal skeleton, and wherein each adjacent position to the phosphorous is either unsubstituted or optionally substituted by nitrogen or an oxygen atom to satisfy the valency of said phosphorous atom. The invention is illustrated schematically below using both aromatic and non-aromatic steroids. Although the isosteric substitution phosphorous atom in the above structures 3–7 is indicated at 13, 14, and 17 positions, it is to be noted that the phosphorous can be substituted at any one of the seventeen positions in non-aromatic or eleven positions in aromatic steroids. The phosphorous atom may be trivalent or tetravalent, and may be radioactive or non-radioactive. The adjacent atoms, X, Y, or Z may be carbon, oxygen, or nitrogen.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: November 13, 2007
    Inventor: Raghavan Rajagopalan
  • Patent number: 7259258
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: August 21, 2007
    Assignee: Illumina, Inc.
    Inventors: Igor Kozlov, Chanfeng Zhao, Galina Steinberg-Tatman
  • Patent number: 7250511
    Abstract: Cyclopenta[g]quinazolines of formula (I), and esters and amides thereof may be made by reacting an ester or amide of formula (II); or a protected derivative thereof with a complex containing the (propargyl)Co2(CO)6+ion
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: July 31, 2007
    Assignee: BTG International Limited
    Inventor: Vassilios Bavetsias
  • Patent number: 7214800
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: May 8, 2007
    Assignees: Cytokinetics, Inc., Smithkline Beecham Corporation
    Inventors: Bainian Feng, Gustave Bergnes, David J. Morgans, Jr., Dashyant Dhanak, Steven David Knight, Michael Gerard Darcy
  • Patent number: 7214794
    Abstract: The present invention is directed to ceramide analog compounds of general formula (I) the process for their preparation and use for the preparation of pharmaceutical formulations for the treatment of tumors
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: May 8, 2007
    Assignee: Bracco S.p.A.
    Inventors: Bruno Macchia, Aldo Balsamo, Marco Macchia, Mario Del Tacca, Romano Danesi